Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors

MAPK/ERK通路 神经母细胞瘤RAS病毒癌基因同源物 MEK抑制剂 癌症研究 克拉斯 激酶 黑色素瘤 曲美替尼 蛋白激酶A 癌症 医学 生物 细胞生物学 内科学 结直肠癌
作者
Erick J. Morris,Sharda Jha,Clifford R. Restaino,Priya Dayananth,Hugh Zhu,Alan Cooper,Donna Carr,Yongi Deng,Weihong Jin,Stuart Black,Brian J. Long,Jenny Liu,Edward DiNunzio,William T. Windsor,Rumin Zhang,Shuxia Zhao,Minilik Angagaw,Elaine M. Pinheiro,Jagdish Desai,Li Xiao,Gerald W. Shipps,Alan Hruza,James Wang,Joe Kelly,Sunil Paliwal,Xiaolei Gao,Boga Sobhana Babu,Liang Zhu,Pierre Daublain,Ling Zhang,Bart Lutterbach,Marc R. Pelletier,Ulrike Philippar,Phieng Siliphaivanh,David Witter,Paul T. Kirschmeier,W. Robert Bishop,Daniel J. Hicklin,D. Gary Gilliland,Lata Jayaraman,Leigh Zawel,Stephen E. Fawell,Ahmed A. Samatar
出处
期刊:Cancer Discovery [American Association for Cancer Research]
卷期号:3 (7): 742-750 被引量:614
标识
DOI:10.1158/2159-8290.cd-13-0070
摘要

Abstract The high frequency of activating RAS or BRAF mutations in cancer provides strong rationale for targeting the mitogen-activated protein kinase (MAPK) pathway. Selective BRAF and MAP-ERK kinase (MEK) inhibitors have shown clinical efficacy in patients with melanoma. However, the majority of responses are transient, and resistance is often associated with pathway reactivation of the extracellular signal-regulated kinase (ERK) signaling pathway. Here, we describe the identification and characterization of SCH772984, a novel and selective inhibitor of ERK1/2 that displays behaviors of both type I and type II kinase inhibitors. SCH772984 has nanomolar cellular potency in tumor cells with mutations in BRAF, NRAS, or KRAS and induces tumor regressions in xenograft models at tolerated doses. Importantly, SCH772984 effectively inhibited MAPK signaling and cell proliferation in BRAF or MEK inhibitor–resistant models as well as in tumor cells resistant to concurrent treatment with BRAF and MEK inhibitors. These data support the clinical development of ERK inhibitors for tumors refractory to MAPK inhibitors. Significance: BRAF and MEK inhibitors have activity in MAPK-dependent cancers with BRAF or RAS mutations. However, resistance is associated with pathway alterations resulting in phospho-ERK reactivation. Here, we describe a novel ERK1/2 kinase inhibitor that has antitumor activity in MAPK inhibitor-naïve and MAPK inhibitor-resistant cells containing BRAF or RAS mutations. Cancer Discov; 3(7); 742–50. ©2013 AACR. See related commentary by Nissan et al., p. 719 This article is highlighted in the In This Issue feature, p. 705
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
1秒前
1秒前
2秒前
pu发布了新的文献求助10
2秒前
田様应助火火火采纳,获得10
3秒前
shang完成签到 ,获得积分10
3秒前
CipherSage应助yc采纳,获得10
4秒前
彭于晏应助Lynn采纳,获得10
4秒前
方方方发布了新的文献求助10
4秒前
5秒前
在水一方应助彩色觅柔采纳,获得10
5秒前
jiao发布了新的文献求助10
6秒前
勤恳马里奥应助HOHO采纳,获得10
6秒前
7秒前
qian发布了新的文献求助10
7秒前
89757完成签到,获得积分10
7秒前
8秒前
英姑应助pu采纳,获得10
8秒前
8秒前
后陡门的夏完成签到,获得积分10
8秒前
夏天完成签到,获得积分10
9秒前
9秒前
1024完成签到,获得积分10
10秒前
10秒前
11秒前
11秒前
lala发布了新的文献求助10
11秒前
jby发布了新的文献求助10
11秒前
xiaoming应助jiao采纳,获得10
11秒前
英姑应助jiao采纳,获得10
11秒前
戴戴完成签到,获得积分10
11秒前
12秒前
科研圈外人完成签到 ,获得积分10
12秒前
12秒前
整齐芷文发布了新的文献求助10
13秒前
Man发布了新的文献求助10
13秒前
芷兰丁香完成签到,获得积分10
14秒前
14秒前
高分求助中
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Bayesian Models of Cognition:Reverse Engineering the Mind 888
Le dégorgement réflexe des Acridiens 800
Defense against predation 800
Very-high-order BVD Schemes Using β-variable THINC Method 568
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3135300
求助须知:如何正确求助?哪些是违规求助? 2786282
关于积分的说明 7776733
捐赠科研通 2442250
什么是DOI,文献DOI怎么找? 1298501
科研通“疑难数据库(出版商)”最低求助积分说明 625124
版权声明 600847